Alpha-bisabolol for Onychomycosis Treatment

Summary

Clinical, interventional, longitudinal study with random sampling. 60 patients will be divided into three groups, group A: control group, drug recommended by the Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with low-level laser therapy, and group C: alpha bisabolol based product. The topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days. Areas of the lesions will be compared.

Timeline

Start

2020-06-01

Primary completion

2020-11-30

Completion

2021-05-01

Drugs

Indications